Do analysts prefer TIL or PLUR?

Instil Bio presently has a consensus price target of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Instil Bio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, TIL or PLUR?

Pluri has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$4.47 N/A Pluri $1.02M 11.62 -$23.82M -$2.45 N/A

Is TIL or PLUR more profitable?

Instil Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Instil Bio's return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -26.78% -14.89% Pluri -2,344.59% N/A -82.71%

Do analysts prefer PLUR or TVGN?

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,306.47%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger earnings and valuation, PLUR or TVGN?

Pluri has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.02M 11.62 -$23.82M -$2.45 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is PLUR or TVGN more profitable?

Tevogen Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Company Net Margins Return on Equity Return on Assets Pluri -2,344.59% N/A -82.71% Tevogen Bio N/A N/A -468.32%

Does the media favor PLUR or TVGN?

In the previous week, Pluri and Pluri both had 3 articles in the media. Pluri's average media sentiment score of 0.83 beat Tevogen Bio's score of 0.45 indicating that Pluri is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend PLUR or HOWL?

Werewolf Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 303.59%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Werewolf Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43

Does the media favor PLUR or HOWL?

In the previous week, Pluri and Pluri both had 3 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.20 beat Pluri's score of 0.83 indicating that Werewolf Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pluri 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PLUR or CELU?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, PLUR or CELU?

Pluri has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pluri $1.02M 11.62 -$23.82M -$2.45 N/A Celularity $26.55M 1.74 -$91.72M -$2.73 N/A

Is PLUR or CELU more profitable?

Celularity has a net margin of -374.87% compared to Pluri's net margin of -2,344.59%. Company Net Margins Return on Equity Return on Assets Pluri -2,344.59% N/A -82.71% Celularity -374.87% N/A -64.45%

Do analysts rate EDSA or PLUR?

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 75.44%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Edesa Biotech is more favorable than Pluri. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EDSA or PLUR more profitable?

Edesa Biotech has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Edesa Biotech N/A -560.22% -105.74% Pluri -2,344.59% N/A -82.71%

Pluri (PLUR) Competitors

$0.94 -0.03 (-3.08%)

Closing price 10/13/2026 03:57 PM Eastern

Extended Trading

$0.96 +0.03 (+2.66%)

As of 05:26 AM Eastern

Compare

PLUR vs. TIL, TVGN, HOWL, CELU, and EDSA

Should you buy Pluri stock or one of its competitors? Pluri's main competitors and comparable companies include Instil Bio (TIL), Tevogen Bio (TVGN), Werewolf Therapeutics (HOWL), Celularity (CELU), and Edesa Biotech (EDSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pluri compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

In the previous week, Pluri had 2 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.79 beat Pluri's score of 0.83 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Pluri	Positive

Instil Bio presently has a consensus price target of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Instil Bio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Instil Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Instil Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-26.78%	-14.89%
Pluri	-2,344.59%	N/A	-82.71%

Instil Bio has a beta of 1.94, indicating that its share price is 94% more volatile than the broader market. Comparatively, Pluri has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

60.6% of Instil Bio shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 47.0% of Instil Bio shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Pluri has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A
Pluri	$1.02M	11.62	-$23.82M	-$2.45	N/A

Summary

Instil Bio beats Pluri on 8 of the 14 factors compared between the two stocks.

How does Pluri compare to Tevogen Bio?

Pluri (NASDAQ:PLUR) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Pluri has higher revenue and earnings than Tevogen Bio. Tevogen Bio is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	11.62	-$23.82M	-$2.45	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Tevogen Bio	N/A	N/A	-468.32%

Pluri has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

In the previous week, Pluri and Pluri both had 3 articles in the media. Pluri's average media sentiment score of 0.83 beat Tevogen Bio's score of 0.45 indicating that Pluri is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tevogen Bio has a consensus target price of $100.00, suggesting a potential upside of 1,306.47%. Given Tevogen Bio's stronger consensus rating and higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

16.6% of Pluri shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 65.6% of Tevogen Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Pluri beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

How does Pluri compare to Werewolf Therapeutics?

Pluri (NASDAQ:PLUR) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Pluri has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Werewolf Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

In the previous week, Pluri and Pluri both had 3 articles in the media. Werewolf Therapeutics' average media sentiment score of 1.20 beat Pluri's score of 0.83 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pluri has higher earnings, but lower revenue than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	11.62	-$23.82M	-$2.45	N/A
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A

Werewolf Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 303.59%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

16.6% of Pluri shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Werewolf Therapeutics beats Pluri on 11 of the 16 factors compared between the two stocks.

How does Pluri compare to Celularity?

Pluri (NASDAQ:PLUR) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Pluri has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Celularity has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Pluri has higher earnings, but lower revenue than Celularity. Celularity is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	11.62	-$23.82M	-$2.45	N/A
Celularity	$26.55M	1.74	-$91.72M	-$2.73	N/A

16.6% of Pluri shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 43.2% of Pluri shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Pluri had 1 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Celularity. Celularity's average media sentiment score of 0.93 beat Pluri's score of 0.83 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
Pluri	Positive
Celularity	Positive

Celularity has a net margin of -374.87% compared to Pluri's net margin of -2,344.59%.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Celularity	-374.87%	N/A	-64.45%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Pluri and Celularity tied by winning 6 of the 12 factors compared between the two stocks.

How does Pluri compare to Edesa Biotech?

Edesa Biotech (NASDAQ:EDSA) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 75.44%. Given Edesa Biotech's stronger consensus rating and higher probable upside, equities analysts clearly believe Edesa Biotech is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Pluri had 2 more articles in the media than Edesa Biotech. MarketBeat recorded 3 mentions for Pluri and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat Pluri's score of 0.83 indicating that Edesa Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Edesa Biotech	Very Positive
Pluri	Positive

Edesa Biotech has higher earnings, but lower revenue than Pluri. Edesa Biotech is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A
Pluri	$1.02M	11.62	-$23.82M	-$2.45	N/A

Edesa Biotech has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Pluri	-2,344.59%	N/A	-82.71%

Edesa Biotech has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Pluri has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market.

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 24.4% of Edesa Biotech shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Edesa Biotech beats Pluri on 9 of the 15 factors compared between the two stocks.

Get Pluri News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLUR vs. The Competition

Export

Metric	Pluri	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$12.23M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.38	10.78	202.90	19.69
Price / Sales	11.62	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	-0.58	16.70	10.61	6.03
Net Income	-$23.82M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-9.62%	-4.43%	-2.89%	-2.34%
1 Month Performance	-23.52%	-12.49%	-7.37%	-5.31%
1 Year Performance	-79.09%	7.63%	3.00%	-2.94%

Pluri Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLUR Pluri	0.7613 of 5 stars	$0.94 -3.1%	N/A	-79.0%	$12.23M	$1.02M	N/A	113	News Coverage
TIL Instil Bio	1.6968 of 5 stars	$6.96 +1.0%	$7.00 +0.6%	-69.7%	$47.19M	N/A	N/A	410
TVGN Tevogen Bio	2.2131 of 5 stars	$6.91 +6.5%	$100.00 +1,347.2%	-80.1%	$44.98M	N/A	N/A	18
HOWL Werewolf Therapeutics	2.6793 of 5 stars	$0.92 0.0%	$4.00 +334.8%	-39.2%	$44.71M	$1.88M	N/A	14	News Coverage Positive News
CELU Celularity	0.6984 of 5 stars	$1.52 -4.1%	N/A	-30.4%	$43.83M	$26.55M	N/A	115	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLUR) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pluri (PLUR) Competitors